T-cell therapy for HLA-A11:01 and KRAS G12V tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a custom immune-cell treatment made from your blood that targets the KRAS G12V change in certain cancers. It is for people with advanced cancer who have already tried standard treatments, and it may help your immune system recognize and attack tumor cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have the KRAS G12V (or closely similar NRAS/HRAS G12V) mutation found by a lab test on tumor tissue
- You must have the HLA-A*11:01 marker on your body confirmed by the trial’s blood-matching lab
- You must have had standard cancer treatment first (then your cancer returned or didn’t respond), or you must have a reason you couldn’t take standard treatment
- You can have up to 3 small, not-too-symptomatic brain metastases (or treated ones that are stable for at least 1 month)
- Your blood counts and organ function (liver/kidneys) must be strong enough for treatment
- You must be HIV and hepatitis B/C negative, and you must avoid pregnancy/breastfeeding during and shortly after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized immune cell treatment made for people with advanced solid cancers that have not responded to standard care. It’s designed for tumors carrying a specific KRAS mutation (G12V or G12D) and for people whose immune “HLA type” matches the therapy.
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
This trial tests a new treatment called IX001 TCR-T cells, which are specially designed immune cells that target a specific mutation (KRAS G12V) found in some pancreatic cancers. It is for people whose cancer has not been controlled by standard chemotherapy.
This trial tests a new treatment called IX001 TCR-T, which uses your own immune cells to target cancer cells with a specific KRAS mutation. It's for people with advanced pancreatic or colorectal cancer who have run out of standard options.
This Phase 1 trial tests a personalized immune-cell treatment (TCR-T cells) for certain metastatic cancers. It targets cancers that carry a specific marker and requires patients to have a specific immune-system match, aiming to improve cancer control when standard options were already tried.
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.